Evidence map›Paper›PMID 42091718›Full record

ReviewApplied microbiology and biotechnology2026

Molecular engineering of Komagataella phaffii for venom toxin production.

Francielle Almeida Cordeiro, Karla de Castro Figueiredo Bordon, Henrique Ranieri Covali-Pontes, Isabela Gobbo Ferreira, Gisele Adriano Wiezel, Isadora Lino Mendes, Malson Neilson de Lucena, Eliane Candiani Arantes

Abstract readReview
In one paragraph

Review in Applied microbiology and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Francielle Almeida CordeiroDepartment of Biomolecular Sciences, Faculty of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP, Brazil. fran_ac@usp.br.
Karla de Castro Figueiredo BordonDepartment of Biomolecular Sciences, Faculty of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP, Brazil.
Henrique Ranieri Covali-PontesInstitute of Biosciences, Federal University of Mato Grosso Do Sul, Campo Grande, MS, Brazil.
Isabela Gobbo FerreiraDepartment of Biomolecular Sciences, Faculty of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP, Brazil.
Gisele Adriano WiezelDepartment of Biomolecular Sciences, Faculty of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP, Brazil.
Isadora Lino MendesDepartment of Biomolecular Sciences, Faculty of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP, Brazil.
Malson Neilson de LucenaInstitute of Biosciences, Federal University of Mato Grosso Do Sul, Campo Grande, MS, Brazil.
Eliane Candiani ArantesDepartment of Biomolecular Sciences, Faculty of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP, Brazil.

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico 306479/2017-6Coordenação de Aperfeiçoamento de Pessoal de Nível Superior 001Fundação de Amparo à Pesquisa do Estado de São Paulo 2023/11264-0Fundação de Amparo à Pesquisa do Estado de São Paulo 2023/11311-9Fundação de Amparo à Pesquisa do Estado de São Paulo 2024/14618-0Fundação de Amparo à Pesquisa do Estado de São Paulo 2025/05917-7
6 · The paper itself

Abstract

Animal venoms constitute a rich source of bioactive peptides and proteins with high target specificity, representing valuable scaffolds for therapeutic development. However, the biotechnological exploitation of venom-derived toxins is limited by challenges in achieving efficient, scalable, and reproducible production. Native venom extraction is constrained by low yields and biological variability, making recombinant platforms essential. Yet, most venom toxins are cysteine-rich peptides with complex disulfide bond architectures and stringent structure-function relationships, posing significant challenges to heterologous expression. Inefficient folding, proteolysis, and secretion bottlenecks frequently compromise functional yield. Among microbial hosts, Komagataella phaffii has emerged as a robust system combining eukaryotic protein processing with high cell-density fermentation and cost-effective cultivation. Its oxidative secretory pathway, strong and regulatable promoters, and suitability for strain engineering make it particularly attractive for producing disulfide-rich toxins. This review provides a critical analysis of recombinant venom toxin production in K. phaffii, focusing on molecular and bioprocess determinants of expression performance. We discuss post-translational modifications, yields, and bioactivity, as well as promoter selection and secretion signal optimization. By integrating data across toxin families, we identify recurring technical bottlenecks and highlight engineering approaches to enhance venom biomanufacturing within microbial biotechnology frameworks.

Indexed as

Genetic EngineeringMetabolic EngineeringSaccharomycetalesVenomsAnimalsFermentationPromoter Regions, GeneticProtein Processing, Post-TranslationalRecombinant ProteinsRecombinant ProteinsVenomsMethylotrophic yeastPichia pastorisPost-translational modificationsRecombinant toxinsVenom-derived peptides

Identifiers

PMID42091718
PMCPMC13315165

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.